Vaughan W P, Karp J E, Burke P J
Cancer. 1980 Mar 1;45(5):859-65. doi: 10.1002/1097-0142(19800301)45:5<859::aid-cncr2820450506>3.0.co;2-z.
Thirty-seven patients with acute myelocytic leukemia were treated with a timed-sequential regimen of arabinosyl cytosine and daunorubicin followed by no further therapy until relapse. The cycle-specific agent arabinosyl cytosine was given by three-day infusion at the time when the malignant cell population was predicted to have a maximal regrowth rate following an initial three-day infusion of arabinosyl cytosine and daunorubicin together. Malignant myeloblasts demonstrated an increased in vivo tritiated thymidine uptake prior to the second infusion. Complete remission was achieved in 56% of previously untreated evaluable patients (65% of all patients less than 60 years of age) with a single cycle of this therapy. Median duration of chemotherapy-free remission for these patients was 10 months, 47% were still in remission at one year and 31% are projected to be in remission at two years. Eight of 11 relapsing patients achieved a second remission with the same regimen and the median survival cannot yet be predicted. These results compare favorably with results from other centers using regimens involving multiple courses of remission induction, consolidation, and continuous maintenance chemotherapy.
37例急性髓细胞白血病患者接受了阿糖胞苷和柔红霉素的定时序贯方案治疗，随后在复发前不再进行进一步治疗。在最初同时输注阿糖胞苷和柔红霉素三天后，预计恶性细胞群体具有最大生长速率时，将细胞周期特异性药物阿糖胞苷进行为期三天的输注。在第二次输注前，恶性成髓细胞的体内氚标记胸腺嘧啶摄取增加。单周期该疗法使56%既往未治疗的可评估患者（所有60岁以下患者的65%）实现完全缓解。这些患者无化疗缓解的中位持续时间为10个月，47%在一年时仍处于缓解状态，预计31%在两年时仍处于缓解状态。11例复发患者中有8例采用相同方案再次缓解，中位生存期尚无法预测。这些结果与其他中心使用涉及多个缓解诱导、巩固和持续维持化疗疗程的方案所取得的结果相比更具优势。
